Gastroesophageal Junction Cancer

• FDA approval · 2025-08-21
  FDA Approved: TRAZIMERA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  FDA approved a supplemental application for TRAZIMERA (trastuzumab-qyyp) from Pfizer Laboratories Div Pfizer Inc, authorizing changes under …

• FDA approval · 2024-11-22
  FDA Approved: PHESGO — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for PHESGO, the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf, submitted…

• FDA approval · 2022-08-05
  FDA Approved: ENHERTU — Supplemental Application (Daiichi Sankyo Inc.)

  FDA approved a supplemental application for ENHERTU (fam-trastuzumab deruxtecan-nxki) from Daiichi Sankyo Inc. to update labeling and/or add…

• FDA approval · 2019-04-17
  FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)

  The FDA approved Biocon Biologics' supplemental application for OGIVRI (trastuzumab-dkst), a trastuzumab biosimilar.

• FDA approval · 2017-03-27
  FDA Approved: HERCEPTIN — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for HERCEPTIN (trastuzumab) submitted by Genentech, Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.